Fibroblast Growth Factor 23 Concentrations in Humoral Hypercalcemia of Malignancy and Hyperparathyroidism
- 31 July 2003
- journal article
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 78 (7), 826-829
- https://doi.org/10.4065/78.7.826
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (DK25409, DK58546)
This publication has 20 references indexed in Scilit:
- Increased Circulatory Level of Biologically Active Full-Length FGF-23 in Patients with Hypophosphatemic Rickets/OsteomalaciaJournal of Clinical Endocrinology & Metabolism, 2002
- Fibroblast Growth Factor (FGF)-23 Inhibits Renal Phosphate Reabsorption by Activation of the Mitogen-activated Protein Kinase PathwayJournal of Biological Chemistry, 2002
- Tumors Associated With Oncogenic Osteomalacia Express Genes Important in Bone and Mineral MetabolismJournal of Bone and Mineral Research, 2002
- Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23Kidney International, 2001
- Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalaciaProceedings of the National Academy of Sciences, 2001
- Fibroblast Growth Factor (FGF)-23 and Hypophosphatemic Rickets/Osteomalacia.Endocrine Journal, 2001
- Phosphatonin - a new phosphaturetic hormone? (Lessons from tumour-induced osteomalacia and X-linked hypophosphataemia)Nephrology Dialysis Transplantation, 1997
- A hypercalcemic nude rat model that completely mimics human syndrome of humoral hypercalcemia of malignancyCalcified Tissue International, 1988
- Sensitivity of the Parathyroid Hormone–1, 25-Dihydroxyvitamin D Axis to Variations in Calcium Intake in Patients with Primary HyperparathyroidismNew England Journal of Medicine, 1985
- The Importance of Circulating 1,25-Dihydroxyvitamin D in the Pathogenesis of Hypercalciuria and Renal-Stone Formation in Primary HyperparathyroidismNew England Journal of Medicine, 1980